Müller Martin C, Saglio Guiseppe, Lin Feng, Pfeifer Heike, Press Richard D, Tubbs Raymond R, Paschka Peter, Gottardi Enrico, O'Brien Steven G, Ottmann Oliver G, Stockinger Hubertus, Wieczorek Lothar, Merx Kirsten, König Heiko, Schwindel Uwe, Hehlmann Rüdiger, Hochhaus Andreas
III. Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany.
Haematologica. 2007 Jul;92(7):970-3. doi: 10.3324/haematol.11172.
Due to the lack of comparability of BCR-ABL mRNA quantification results generated by various methodologies in different laboratories, an international multicenter trial was started with the participation of six laboratories (platforms: LightCycler LC, n=3; TaqMan TM, n=3). One hundred and eighty-six PB samples derived from healthy donors were spiked with serial dilutions (1:20 to 1:2x10(6)) of b2a2, b3a2 or e1a2 BCR-ABL positive white blood cells (WBC) from leukemic patients. After PAXgene stabilization, blinding, freezing and distribution, standardized RNA extraction, cDNA synthesis, PCR protocols and data evaluation were carried out. There was no significant difference in the results achieved using LC and TM technologies, but a considerable overall variation (CV=0.74 for ratios BCR-ABL/ABL). Up to a dilution of 1:1,000, 27/30 of the 2.5 mL samples tested positive. For higher dilutions, a PB volume of 5 or 10 ml was required to improve sensitivity. The study showed the feasibility of RQ-PCR standardization independent of the PCR machine used.
由于不同实验室采用的各种方法所产生的BCR-ABL mRNA定量结果缺乏可比性,一项由六个实验室参与的国际多中心试验启动(平台:LightCycler LC,n = 3;TaqMan TM,n = 3)。从健康供体采集的186份外周血(PB)样本中加入来自白血病患者的b2a2、b3a2或e1a2 BCR-ABL阳性白细胞(WBC)的系列稀释液(1:20至1:2×10⁶)。在进行PAXgene稳定、盲法处理、冷冻和分发后,开展标准化的RNA提取、cDNA合成、PCR方案及数据评估。使用LC和TM技术所获得的结果无显著差异,但总体存在相当大的变异性(BCR-ABL/ABL比值的CV = 0.74)。在稀释至1:1000时,所检测的2.5 mL样本中有27/30呈阳性。对于更高的稀释度,需要5或10 mL的PB体积以提高灵敏度。该研究表明了独立于所用PCR机器的RQ-PCR标准化的可行性。